This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. CYBN, BIOA, VIRI, WHWK, PYRGF, OSTX, ATNM, EGRX, ELYM, and NBRVShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), and Nabriva Therapeutics (NBRV). Vital Therapies vs. Its Competitors Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada OS Therapies Actinium Pharmaceuticals Eagle Pharmaceuticals Eliem Therapeutics Nabriva Therapeutics Vital Therapies (NASDAQ:VTL) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation. Which has more volatility & risk, VTL or CYBN? Vital Therapies has a beta of 3.51, indicating that its share price is 251% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Do insiders and institutionals have more ownership in VTL or CYBN? 15.5% of Vital Therapies shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 33.9% of Vital Therapies shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to VTL or CYBN? In the previous week, Cybin had 1 more articles in the media than Vital Therapies. MarketBeat recorded 1 mentions for Cybin and 0 mentions for Vital Therapies. Cybin's average media sentiment score of 0.34 beat Vital Therapies' score of 0.00 indicating that Cybin is being referred to more favorably in the news media. Company Overall Sentiment Vital Therapies Neutral Cybin Neutral Is VTL or CYBN more profitable? Cybin's return on equity of -37.58% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Cybin N/A -37.58%-36.59% Do analysts rate VTL or CYBN? Cybin has a consensus price target of $85.00, indicating a potential upside of 1,024.34%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has preferable valuation & earnings, VTL or CYBN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/ACybinN/AN/A-$57.88M-$3.88-1.95 SummaryCybin beats Vital Therapies on 9 of the 12 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.47M$763.52M$5.48B$9.51BDividend YieldN/A4.84%4.73%4.09%P/E RatioN/A1.3428.6723.80Price / SalesN/A25.20373.9066.58Price / CashN/A19.5635.4557.96Price / Book3.216.778.275.55Net Income-$41.47M-$4.28M$3.24B$259.03M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$0.93-0.9%N/A-34.3%$39.47MN/A0.0010Gap DownCYBNCybin2.5864 of 5 stars$7.57-2.2%$85.00+1,022.9%N/A$178.58MN/A-1.7350BIOABioAge LabsN/A$4.48-1.1%N/AN/A$160.61MN/A0.00N/APositive NewsVIRIVirios TherapeuticsN/A$4.82+1.0%$5.00+3.7%+2,247.1%$92.82MN/A-17.855Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.77-2.2%N/AN/A$83.39M$25.98M11.0640PYRGFPyroGenesis Canada0.3773 of 5 stars$0.29+0.7%N/A-53.5%$54.23M$9.14M-4.8390News CoverageGap UpHigh Trading VolumeOSTXOS Therapies2.1036 of 5 stars$1.83+1.7%$18.00+883.6%N/A$51.42MN/A-2.13N/AATNMActinium Pharmaceuticals1.9811 of 5 stars$1.61-6.4%$4.00+148.4%-75.6%$50.23MN/A-1.1630News CoveragePositive NewsEGRXEagle Pharmaceuticals1.9805 of 5 stars$3.69flatN/A-33.3%$47.92M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.60+10.3%N/A-80.9%$47.60MN/A-3.029NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies CYBN Competitors BIOA Competitors VIRI Competitors WHWK Competitors PYRGF Competitors OSTX Competitors ATNM Competitors EGRX Competitors ELYM Competitors NBRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
